Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Ravdin

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|August 1, 1997
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancerP M Ravdin
Oncology (Williston Park, N.Y.)|March 1, 1997
The international experience with docetaxel in the treatment of breast cancerP M Ravdin
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Anthracycline resistance in breast cancer: clinical applications of current knowledgeP M Ravdin
Seminars in Oncology|December 1, 1995
Taxoids: effective agents in anthracycline-resistant breast cancerP M Ravdin
Breast Cancer Research and Treatment|January 1, 1993
Evaluation of cathepsin D as a prognostic factor in breast cancerP M Ravdin
Seminars in Oncology|July 30, 1999
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancerP M Ravdin
Seminars in Oncology|September 11, 1999
Should HER2 status be routinely measured for all breast cancer patients?P M Ravdin
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
How can prognostic and predictive factors in breast cancer be used in a practical way today?P M Ravdin
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patientsP M Ravdin
Journal of the National Cancer Institute. Monographs|January 5, 2002
Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yesP M Ravdin
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|August 1, 1997
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancerP M Ravdin
Oncology (Williston Park, N.Y.)|March 1, 1997
The international experience with docetaxel in the treatment of breast cancerP M Ravdin
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Anthracycline resistance in breast cancer: clinical applications of current knowledgeP M Ravdin
Seminars in Oncology|December 1, 1995
Taxoids: effective agents in anthracycline-resistant breast cancerP M Ravdin
Breast Cancer Research and Treatment|January 1, 1993
Evaluation of cathepsin D as a prognostic factor in breast cancerP M Ravdin
Seminars in Oncology|July 30, 1999
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancerP M Ravdin
Seminars in Oncology|September 11, 1999
Should HER2 status be routinely measured for all breast cancer patients?P M Ravdin
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
How can prognostic and predictive factors in breast cancer be used in a practical way today?P M Ravdin
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patientsP M Ravdin
Journal of the National Cancer Institute. Monographs|January 5, 2002
Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yesP M Ravdin
Pageof 6